IDEAS home Printed from https://ideas.repec.org/a/epw/clinic/v3y2022i1id12159.html

Omicron Variant (B.1.1.529) of SARS-CoV-2, A Worldwide Public Health Emergency!

Author

Listed:
  • Selia Chowdhury
  • Mehedi Hasan Bappy
  • Samia Chowdhury
  • Md. Shahraj Chowdhury
  • Nurjahan Shipa Chowdhury

Abstract

B.1.1.529 is the newest form of SARS- CoV-2. It was initially reported to the World Health Organization (WHO) on November 24, 2021, by South Africa. WHO recognized it as a variant of concern on November 26, 2021, and named it "Omicron.” The Omicron variant features an exceptionally large number of mutations, many of which are unique, and a substantial number of which impair the spike protein targeted by most COVID-19 vaccines at the time of its discovery. Despite initial studies showing that the variant caused less serious disease than prior strains, this amount of miscellany has raised worries about its transmissibility, immune system evasion, and vaccine resistance. Omicron is suspected to be much more infectious than previous variants of concerns, spreading around 70 times faster in the bronchi, but it is less able to penetrate deep lung tissue, which may explain why there is a significant reduction in the risk of severe disease requiring hospitalization. Nonetheless, because of the virus's fast rate of transmission and capacity to resist both two-dose vaccination and the immune system, the overall number of patients requiring medical care at present remains a major worry. In this article, the current state of the art for Omicron variant has been discussed to provide a strong framework for future research. The evolution, mutation, epidemiology, infectivity, vaccine breakthrough, and antibody resistance of the Omicron variant are investigated and discussed.

Suggested Citation

  • Selia Chowdhury & Mehedi Hasan Bappy & Samia Chowdhury & Md. Shahraj Chowdhury & Nurjahan Shipa Chowdhury, 2022. "Omicron Variant (B.1.1.529) of SARS-CoV-2, A Worldwide Public Health Emergency!," European Journal of Clinical Medicine, European Open Science, vol. 3(1), pages 5-9, January.
    • Handle: RePEc:epw:clinic:v:3:y:2022:i:1:id:12159
    DOI: 10.24018/clinicmed.2022.3.1.159
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/clinicmed/article/view/12159
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/clinicmed/article/download/12159/2447
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/clinicmed.2022.3.1.159?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Chunyan Wang & Wentao Li & Dubravka Drabek & Nisreen M. A. Okba & Rien Haperen & Albert D. M. E. Osterhaus & Frank J. M. Kuppeveld & Bart L. Haagmans & Frank Grosveld & Berend-Jan Bosch, 2020. "Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection," Nature Communications, Nature, vol. 11(1), pages 1-1, December.
    2. Selia Chowdhury & Mehedi Hasan Bappy & Samia Chowdhury & Md. Shahraj Chowdhury & Nurjahan Shipa Chowdhury, 2021. "COVID-19 Induced Cardiovascular Complications and Recent Therapeutic Advances," European Journal of Medical and Health Sciences, European Open Science, vol. 3(6), pages 17-22, November.
    3. Selia Chowdhury & Mehedi Hasan Bappy & Samia Chowdhury & Md. Shahraj Chowdhury & Nurjahan Shipa Chowdhury, 2021. "Current Review of Delta Variant of SARS-CoV-2," European Journal of Medical and Health Sciences, European Open Science, vol. 3(6), pages 23-29, November.
    4. Chunyan Wang & Wentao Li & Dubravka Drabek & Nisreen M. A. Okba & Rien Haperen & Albert D. M. E. Osterhaus & Frank J. M. Kuppeveld & Bart L. Haagmans & Frank Grosveld & Berend-Jan Bosch, 2020. "A human monoclonal antibody blocking SARS-CoV-2 infection," Nature Communications, Nature, vol. 11(1), pages 1-6, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Yifan Wang & Caixuan Liu & Chao Zhang & Yanxing Wang & Qin Hong & Shiqi Xu & Zuyang Li & Yong Yang & Zhong Huang & Yao Cong, 2022. "Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    2. Lei Peng & Yingxia Hu & Madeleine C. Mankowski & Ping Ren & Rita E. Chen & Jin Wei & Min Zhao & Tongqing Li & Therese Tripler & Lupeng Ye & Ryan D. Chow & Zhenhao Fang & Chunxiang Wu & Matthew B. Dong, 2022. "Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    3. Erkin Kuru & Jonathan Rittichier & Helena Puig & Allison Flores & Subhrajit Rout & Isaac Han & Abigail E. Reese & Thomas M. Bartlett & Fabio Moliner & Sylvie G. Bernier & Jason D. Galpin & Jorge March, 2024. "Rapid discovery and evolution of nanosensors containing fluorogenic amino acids," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    4. Safiyanu, Babangida Danladi & Isa, Musa & Lawan, Isah Isah, 2020. "Impact of COVID-19 on the Nigerian Stock Exchange Market," MPRA Paper 110408, University Library of Munich, Germany.
    5. Franziska K. Kaiser & Mariana Gonzalez Hernandez & Nadine Krüger & Ellinor Englund & Wenjuan Du & Anna Z. Mykytyn & Mathijs P. Raadsen & Mart M. Lamers & Francine Rodrigues Ianiski & Tatiana M. Shamor, 2024. "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    6. Selia Chowdhury & Mehedi Hasan Bappy, 2021. "On the Delta Plus Variant of SARS-CoV-2," European Journal of Medical and Health Sciences, European Open Science, vol. 3(6), pages 52-55, November.
    7. Garazi Peña Alzua & André Nicolás León & Temima Yellin & Disha Bhavsar & Madhumathi Loganathan & Kaitlyn Bushfield & Philip J. M. Brouwer & Alesandra J. Rodriguez & Trushar Jeevan & Richard Webby & Ch, 2026. "Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin," Nature Communications, Nature, vol. 17(1), pages 1-11, December.
    8. Chunyan Wang & Emma L. Hesketh & Tatiana M. Shamorkina & Wentao Li & Peter J. Franken & Dubravka Drabek & Rien Haperen & Sarah Townend & Frank J. M. Kuppeveld & Frank Grosveld & Neil A. Ranson & Joost, 2022. "Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    9. Niels Joachim Gormsen & Ralph S J Koijen & Nikolai Roussanov, 0. "Coronavirus: Impact on Stock Prices and Growth Expectations," The Review of Asset Pricing Studies, Society for Financial Studies, vol. 10(4), pages 574-597.
    10. P. K. Mishra & S. K. Mishra, 2020. "Corona Pandemic and Stock Market Behaviour: Empirical Insights from Selected Asian Countries," Millennial Asia, , vol. 11(3), pages 341-365, December.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:clinic:v:3:y:2022:i:1:id:12159. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/clinicmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.